觀察個(gè)性化健康管理干預(yù)用于急慢性胃炎患者的臨床效果及對(duì)服藥依從性的影響價(jià)值
【摘要】目的:研究個(gè)性化健康管理干預(yù)對(duì)急慢性胃炎患者的效果。方法:納入2022年2月8日—2023年10月7日收治的30例急慢性胃炎患者,采用隨機(jī)數(shù)字表法將其分為對(duì)照組和試驗(yàn)組。對(duì)照組(15例)實(shí)施常規(guī)干預(yù),試驗(yàn)組(15例)實(shí)施常規(guī)干預(yù)聯(lián)合個(gè)性化健康管理干預(yù)。觀察兩組干預(yù)效果。結(jié)果:干預(yù)4周后,試驗(yàn)組的急慢性胃炎健康知識(shí)掌握評(píng)分及服藥依從性評(píng)分[(85.67±4.16)分及(7.58±0.41)分]均高于對(duì)照組[(71.33±3.81)分及(5.88±0.23)分],P
【關(guān)鍵詞】個(gè)性化健康管理干預(yù);急慢性胃炎;服藥依從性
Observation of the clinical effect of personalized health management intervention on patients with acute and chronic gastritis and its impact value on medication compliance
ZHANG Jie
Community Health Service Center of Taiping Street Office in Ji’nan Qibu District, Jinan, Shandong 251407, China
【Abstract】Objective:To study the effect of personalized health management intervention on patients with acute and chronic gastritis. Methods:Thirty patients with acute and chronic gastritis admitted from February 8,2022 to October 7,2023 were included and divided into the control group and the experimental group using a random number table method.The control group (15 cases)received routine intervention,and the experimental group (15 cases)receivedroutineintervention combined with personalized health management intervention.The intervention effects of the two groups were observed.Results:After 4 weeks of intervention,the health knowledge mastery for acute and chronic gastritis score and medication compliance score of the experimental group [(85.67±4.16) points and (7.58±0.41) points] were higher than those of the control group [(71.33±3.81) points and (5.88±0.23) points],P
【Key?Words】Personalized health management intervention; Acute and chronic gastritis; Medication compliance
急慢性胃炎是胃部的急慢性炎癥疾病類(lèi)型,在臨床上的就診率較高[1]。(剩余4139字)
- 助產(chǎn)士連續(xù)護(hù)理對(duì)妊娠結(jié)局的影響...
- 血栓彈力圖檢測(cè)在產(chǎn)后大出血產(chǎn)婦...
- 不同凍胚方案改善反復(fù)種植失敗患...
- 婦科千金膠囊和去氧孕烯炔雌醇片...
- 固腎保胎湯對(duì)先兆流產(chǎn)患者激素水...
- 預(yù)防性護(hù)理干預(yù)聯(lián)合Kegel運(yùn)...
- 妊娠期高血壓疾病的妊娠結(jié)局分析...
- 產(chǎn)后保健對(duì)產(chǎn)婦產(chǎn)后恢復(fù)以及新生...
- 整體責(zé)任制護(hù)理在無(wú)痛分娩助產(chǎn)中...
- 無(wú)痛分娩護(hù)理干預(yù)對(duì)產(chǎn)婦產(chǎn)程的影...
- 宮頸上皮內(nèi)腫瘤患者陰道微生態(tài)失...
- 婦科泌尿生殖道病原微生物檢測(cè)結(jié)...
- 垂體后葉素聯(lián)合腹腔鏡切除術(shù)在子...
- 超聲膀胱容量監(jiān)測(cè)技術(shù)在宮頸癌調(diào)...
- 老年性陰道炎藥物治療闡述...
- 神經(jīng)內(nèi)鏡下手術(shù)治療基底節(jié)區(qū)高血...
- 觀察分子生物學(xué)技術(shù)應(yīng)用于病原微...
- 感官刺激在VATS肺葉切除術(shù)后...
- 體外圈套器牽引輔助內(nèi)鏡黏膜下剝...
- 腹股溝疝無(wú)張力修補(bǔ)與TAPP在...
- 無(wú)托槽隱形矯治在口腔正畸治療中...
- 硬膜外阻滯聯(lián)合全身麻醉對(duì)前列腺...
- 磁共振和CT對(duì)評(píng)估早期直腸癌前...
- 艾司西酞普蘭對(duì)抑郁癥患者的治療...
- 曲美他嗪聯(lián)合美托洛爾對(duì)冠心病心...
- 不同濃度羅哌卡因腹橫筋膜神經(jīng)阻...
- 倍他司汀、天麻素注射液聯(lián)合異丙...
- 聯(lián)合應(yīng)用蘇黃止咳膠囊與茶堿緩釋...
- 二甲雙胍聯(lián)合恩格列凈治療2型糖...
- 藥學(xué)干預(yù)對(duì)臨床不合理用藥的意義...
- 葡萄糖水聯(lián)合非營(yíng)養(yǎng)性吸吮對(duì)緩解...
- 妊娠期高血壓治療中拉貝洛爾與硫...
- 探索快速康復(fù)護(hù)理聯(lián)合中醫(yī)特色治...
- 中(朝)醫(yī)適宜技術(shù)在治療女性更...
- 桂枝芍藥湯治療腰腿痛寒濕證效果...
- 基于“五行相克”中醫(yī)情志療法調(diào)...
- 中醫(yī)適宜技術(shù)聯(lián)合任務(wù)導(dǎo)向性訓(xùn)練...
- 在小兒哮喘急性發(fā)作期霧化吸入治...
- 血細(xì)胞檢驗(yàn)對(duì)小兒上呼吸道感染H...
- 血清C反應(yīng)蛋白、降鈣素原及白細(xì)...
- 蒙脫石散聯(lián)用復(fù)合乳酸菌膠囊對(duì)腹...
- 綜合護(hù)理干預(yù)在小兒過(guò)敏性紫癜護(hù)...
- 優(yōu)質(zhì)護(hù)理在小兒肺炎支原體感染治...
- 維生素D缺乏對(duì)某高原地區(qū)學(xué)齡期...
- PDCA干預(yù)在小兒內(nèi)科住院患兒...
- 心理干預(yù)在圍絕經(jīng)期綜合征患者中...
- 優(yōu)質(zhì)護(hù)理在妊娠合并前置胎盤(pán)患者...
- 分析在妊娠高血壓患者手術(shù)室護(hù)理...
- 優(yōu)質(zhì)護(hù)理在兒科肺炎護(hù)理中的應(yīng)用...
- 集束化護(hù)理對(duì)髖關(guān)節(jié)骨折患者再次...
- 心理干預(yù)聯(lián)合臨床護(hù)理路徑對(duì)精神...
- 早期康復(fù)護(hù)理模式在腦梗死護(hù)理中...
- 綜合護(hù)理干預(yù)在腦卒中繼發(fā)癲癇患...
- 全程優(yōu)化急診護(hù)理在急性心肌梗死...
- 延續(xù)性護(hù)理干預(yù)在肺癌化療患者中...
- 護(hù)理干預(yù)結(jié)合腸內(nèi)營(yíng)養(yǎng)護(hù)理對(duì)重癥...
- 理性情緒療法結(jié)合引導(dǎo)護(hù)理在雙相...
- 細(xì)節(jié)化優(yōu)質(zhì)護(hù)理服務(wù)對(duì)腦梗死患者...
- 基于MDT的階梯護(hù)理干預(yù)對(duì)急性...
- 手術(shù)室優(yōu)質(zhì)護(hù)理對(duì)玻璃體切割術(shù)患...
- 針對(duì)性護(hù)理在急性重癥腦梗死患者...
- 紅光治療失禁性皮炎的心理護(hù)理及...
- 健康教育在消化性潰瘍護(hù)理中的應(yīng)...
- 綜合健康教育對(duì)HPV陽(yáng)性患者的...
- 觀察個(gè)性化健康管理干預(yù)用于急慢...
- 回授法健康教育對(duì)2型糖尿病患者...